ecteinascidin 743 has been researched along with pioglitazone in 1 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (pioglitazone) | Trials (pioglitazone) | Recent Studies (post-2010) (pioglitazone) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 4,338 | 824 | 2,277 |
| Protein | Taxonomy | ecteinascidin 743 (IC50) | pioglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1 | |
| Bile salt export pump | Rattus norvegicus (Norway rat) | 2 | |
| Peroxisome proliferator-activated receptor gamma | Rattus norvegicus (Norway rat) | 0.7 | |
| Bile salt export pump | Homo sapiens (human) | 0.337 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.114 | |
| Steryl-sulfatase | Homo sapiens (human) | 0.8 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 1.15 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.298 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 3.0379 | |
| Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | 0.7 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 4.8 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 8.65 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballabio, S; Bello, E; Brich, S; Carrassa, L; Casali, PG; Craparotta, I; D'Incalci, M; Frapolli, R; Gronchi, A; Mannarino, L; Marchini, S; Pilotti, S; Ponzo, M; Porcu, L; Sanfilippo, R; Ubezio, P | 1 |
1 other study(ies) available for ecteinascidin 743 and pioglitazone
| Article | Year |
|---|---|
Combination of PPARĪ³ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Topics: Adipocytes; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Drug Resistance, Neoplasm; Female; Humans; Hypoglycemic Agents; Liposarcoma, Myxoid; Mice; Mice, Nude; Pioglitazone; PPAR gamma; Trabectedin; Xenograft Model Antitumor Assays | 2019 |